Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: NCT00984048).
Suzan McNamara(Quebec - Clinical Research Organization in Cancer), Gerald Batist(Jewish General Hospital), Cyrla Hoffert(Quebec - Clinical Research Organization in Cancer), Petr Kavan(Université Paris Cité), Daniel Fornika(Simon Fraser University), Errol Camlioglu(Jewish General Hospital), Maud Marques(IGNIS Innovation (Canada)), Micheal Witcher(Jewish General Hospital), Rosemary M. McCloskey(University of British Columbia), Adriana Aguilar(Jewish General Hospital), Adrian Gologan(Jewish General Hospital), Benoit Têtu(Hôpital du Saint-Sacrement), Mathilde Couëtoux du Tertre(Quebec - Clinical Research Organization in Cancer), Thérèse Gagnon-Kugler(Quebec - Clinical Research Organization in Cancer), Zuanel Diaz(Quebec - Clinical Research Organization in Cancer), Félix Couture, Ève St‐Hilaire(Dr. Georges-L.-Dumont University Hospital Centre), Hans Prenen(Antwerp University Hospital), Thierry Alcindor(McGill University), Lucas Sidéris(McGill University Health Centre), Richard Dalfen(St Mary's Hospital Centre), Ryan D. Morin(Simon Fraser University), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Ronald L. Burkes(Mount Sinai Hospital), Bernard Lespérance(Hôpital du Sacré-Cœur de Montréal), Sabine Tejpar(Unknown), Yoo‐Joung Ko(Sunnybrook Health Science Centre), André Constantin(Jewish General Hospital), Samia Qureshi(Quebec - Clinical Research Organization in Cancer), Benoît Samson(Hôpital Charles-Le Moyne), Celia M.T. Greenwood(University of Toronto)
Cited by 0
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
|Cancer Cell|2020|1.1k
Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary
|New England Journal of Medicine|2009|775